Alkermes

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alkermes reports robust Q4 earnings, eyes growth through innovative products

Alkermes demonstrated strong financial performance in Q4 2022, driven by the successful launch of LYBALVI and continued growth in key products.
The company's focus on expanding market access, enhancing product awareness, and strategic investments position it for future success and revenue growth.
Challenges in meeting revenue targets, managing profitability, and refining market strategies require careful navigation and proactive decision-making.
Opportunities in advancing product launches, expanding the pipeline, and leveraging scientific advancements offer avenues for sustained growth and market leadership.

Alkermes reports robust Q1 earnings, eyes global expansion and innovation

Alkermes delivered strong financial results in Q1 2023, driven by key proprietary products and strategic initiatives like the LYBALVI direct-to-consumer campaign.
While facing challenges such as commercial pressures and financial optimization queries, the company remains focused on growth and profitability.
Opportunities for international expansion, strategic investments, and innovative drug development position Alkermes for future success and value creation for shareholders.

Alkermes reports strong Q2 earnings, eyes growth through strategic initiatives

Alkermes' Q2 2023 Earnings Call reflects robust financial performance, strategic focus on key products, and ongoing investment in growth opportunities. Resolving arbitration, strong net income, and cash position underscore financial strength amidst operational challenges.

Alkermes posts solid Q3 results, plans neuroscience focus post-separation

Alkermes delivered strong Q3 results with revenue growth across key products and a focus on disciplined cost management post-separation.
The company showcased promising data for ALKS 2680 and outlined strategic priorities to drive future growth in the neuroscience sector.
While challenges like managing expenses and addressing safety concerns exist, opportunities in expanding product offerings and market access strategies are key for future success.
Investors should monitor Alkermes' progress in optimizing dosing profiles, mitigating adverse events, and achieving profitability targets amidst competitive pressures.

Alkermes reports stellar 2023 results, eyes transformative neuroscience advancements

Alkermes' strong financial performance in 2023 sets the stage for continued growth and innovation in 2024.
Key products like LYBALVI, ARISTADA, and VIVITROL demonstrated robust sales growth, underpinning the company's success.
Addressing challenges such as liver toxicity and visual disturbances will be crucial for sustaining growth and product development.
Opportunities in advancing neuroscience studies and capital allocation strategies position Alkermes for future success and value creation.

Alkermes reports strong Q1 earnings, eyes growth through product differentiation

Alkermes' Q1 performance reflects solid revenue growth and profitability, driven by key product successes.
While facing challenges such as expense management and market access, the company remains well-positioned.
Opportunities for growth lie in expanding prescriber base, accelerating revenue, and leveraging product strengths.
Overall, Alkermes demonstrates financial resilience and strategic focus on sustainable growth.

Alkermes (ALKS) reports robust Q2 earnings, focuses on growth strategies

Alkermes (ALKS) delivered strong revenue performance in Q2 2024, driven by proprietary product growth and effective expense management.
The company showcased resilience amidst revenue challenges and emphasized strategic initiatives for profitability and pipeline advancement.
While facing industry challenges, Alkermes remains poised for growth through innovation, market expansion, and operational efficiency.
Strategic focus on advancing key products, exploring growth opportunities, and prudent financial management underpin Alkermes' growth trajectory.

Alkermes excels in Q3 earnings, targets $200M EBITDA in 2025

Alkermes demonstrated strong sales performance in Q3 2024, with a strategic focus on profitability and cash flow for the future. While facing challenges in certain revenue streams, the company is poised to capitalize on growth opportunities and drive financial success in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

Alkermes plc (NASDAQ:ALKS ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Todd Nichols - Chief Commercial Officer Iain Brown - Chief Financial Officer Richard Pops - Chief Executive Officer Conference Call Participants David Amsellem - Piper Sandler Akash Tiwari - Jeffries Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs Paul Matteis - Stifel Uy Ear - Mizuho Jason Gerberry - Bank of America Jessica Fye - J.P. Morgan Marc Goodman - SVB Douglas Tsao - H.C.

Alkermes plc (ALKS) Q4 2022 Earnings Call Transcript

Seagen

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared. The post Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out appeared first on Investor's Business Daily.

Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out

Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates

—  Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 — —  Achieved LYBALVI® Net Sales of $96.0 Million in First Full Year of Commercial Launch — —  Accelerated Long-Term Profitability Targets Reflect Enhanced Profitability Driven by Planned Separation of Oncology Business — DUBLIN , Feb. 16, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2022 and provided financial expectations for 2023. "2022 was a productive year for Alkermes as we delivered strong results for the first full year of the commercial launch of LYBALVI®, achieved double-digit revenue growth for VIVITROL® and ARISTADA®, and continued to advance our R&D portfolio, including ongoing enrollment of the potential registration-enabling studies for nemvaleukin in oncology and initiation of the first-in-human studies for our orexin 2 receptor agonist program," said Richard Pops, Chief Executive Officer of Alkermes.

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023

DUBLIN , Feb. 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

— Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK —   DUBLIN , Jan. 17, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (nemvaleukin), the company's investigational, novel engineered interleukin-2 (IL-2) variant immunotherapy, has been granted an Innovation Passport for the treatment of mucosal melanoma under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK). The Innovation Passport designation is the entry point to the ILAP, which aims to accelerate time to market and facilitate patient access to medicines in the UK for life-threatening or seriously debilitating conditions, or conditions for which there is a significant patient or public health need.

Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

Alkermes' planned spinoff of its oncology assets could establish a long-term compounder with interesting economics tied in. Financial details on the planned move are light, with further information set to be released early this year.

Alkermes Oncology Spinoff Could Eventuate An Alpha Play, Rate Buy

DUBLIN , Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference.

Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?

DUBLIN , Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET (1:00 p.m.

Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Alkermes (ALKS) Stock Stands Out in a Strong Industry

DUBLIN , Nov. 22, 2022 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 29, 2022 at 2:40 p.m. ET (7:40 p.m.

Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

DUBLIN , Nov. 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022 at 8:00 a.m. ET (1:00 p.m.

Alkermes to Participate in the Stifel Healthcare Conference

Alkermes plc (NASDAQ:ALKS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Richard Pops - CEO Iain Brown - CFO Todd Nichols - CCO Conference Call Participants Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs Brandon Folkes - Cantor Fitzgerald Uy Ear - Mizuho David Amsellem - Piper Sandler Marc Goodman - SVB Securities Jason Gerberry - Bank of America Operator Greetings, and welcome to the Alkermes Third Quarter 2022 Financial Results Conference Call. My name is Melissa, and I will be your operator for today's call.

Alkermes plc (ALKS) Q3 2022 Earnings Call Transcript

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Q3 Earnings Match Estimates

—  Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — —  GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0. 02 — —  Company Announces Intent to Separate Oncology Business — —  Company Updates Financial Expectations for Full-Year 2022 — DUBLIN , Nov. 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2022 and updated certain financial expectations for full-year 2022.

Alkermes plc Reports Third Quarter 2022 Financial Results

— Alkermes to Focus on Profitable Growth of Pure-Play, Commercial-Stage Neuroscience Business — — Separation Expected to Unlock Value Through Sharpened Strategic Focus, Simplified Capital Allocation Decision-Making, and Distinct Investment Profiles — — Company to Host Webcast Today at 8 a.m. ET — DUBLIN , Nov. 2, 2022 /PRNewswire/ --Alkermes plc (Nasdaq: ALKS) today announced approval by its Board of Directors (the Board) to explore separating its commercial-stage neuroscience business and development-stage oncology business.

Alkermes plc Announces Intent to Separate Oncology Business

–  6th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer – DUBLIN , Oct. 27, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2022 recipients of the Alkermes Inspiration Grants® program. Grants were awarded to nine nonprofit organizations working to address the needs of people living with alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and cancer.

Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program

DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.

Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022

Acorda Therapeutics

Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case

Allakos Inc

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Alkermes, Allakos See Activist Action

-- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project -- -- Application Period Open Until Nov. 30, 2022 -- DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it is now accepting applications for its annual Alkermes Pathways Research Awards® program.

News for Alkermes Stock (ALKS)